Merck Provides Update on Keyvibe and Keyform Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations With Pembrolizumab
默沙東提供關於Keyvibe和Keyform臨床開發項目的更新，評估對照試驗中的Vibostolimab和Favezelimab與Pembrolizumab的固定劑量組合。
